337 related articles for article (PubMed ID: 25612613)
1. Epidemiology and management of gout in Taiwan: a nationwide population study.
Kuo CF; Grainge MJ; See LC; Yu KH; Luo SF; Zhang W; Doherty M
Arthritis Res Ther; 2015 Jan; 17(1):13. PubMed ID: 25612613
[TBL] [Abstract][Full Text] [Related]
2. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.
Kuo CF; Grainge MJ; Mallen C; Zhang W; Doherty M
Ann Rheum Dis; 2015 Apr; 74(4):661-7. PubMed ID: 24431399
[TBL] [Abstract][Full Text] [Related]
3. Incidence and prevalence of gout in Western Sweden.
Dehlin M; Drivelegka P; Sigurdardottir V; Svärd A; Jacobsson LT
Arthritis Res Ther; 2016 Jul; 18():164. PubMed ID: 27412614
[TBL] [Abstract][Full Text] [Related]
4. The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.
Rai SK; Aviña-Zubieta JA; McCormick N; De Vera MA; Shojania K; Sayre EC; Choi HK
Semin Arthritis Rheum; 2017 Feb; 46(4):451-456. PubMed ID: 28040245
[TBL] [Abstract][Full Text] [Related]
5. Urate-lowering treatment and risk of total joint replacement in patients with gout.
Kuo CF; Chou IJ; See LC; Chen JS; Yu KH; Luo SF; Hsieh AH; Zhang W; Doherty M
Rheumatology (Oxford); 2018 Dec; 57(12):2129-2139. PubMed ID: 30060176
[TBL] [Abstract][Full Text] [Related]
6. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
7. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
Hakoda M; Kasagi F
Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
[No Abstract] [Full Text] [Related]
8. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.
Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Schumacher HR; Saag KG
Ann Rheum Dis; 2005 Feb; 64(2):267-72. PubMed ID: 15647434
[TBL] [Abstract][Full Text] [Related]
9. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study.
Trifirò G; Morabito P; Cavagna L; Ferrajolo C; Pecchioli S; Simonetti M; Bianchini E; Medea G; Cricelli C; Caputi AP; Mazzaglia G
Ann Rheum Dis; 2013 May; 72(5):694-700. PubMed ID: 22736095
[TBL] [Abstract][Full Text] [Related]
11. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007.
Elliot AJ; Cross KW; Fleming DM
Ann Rheum Dis; 2009 Nov; 68(11):1728-33. PubMed ID: 19029167
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
Mohammed E; Browne LD; Kumar A U A; Adeeb F; Fraser AD; Stack AG
PLoS One; 2019; 14(1):e0210487. PubMed ID: 30682034
[TBL] [Abstract][Full Text] [Related]
13. Contemporary epidemiology of gout in the UK general population.
Cea Soriano L; Rothenbacher D; Choi HK; García Rodríguez LA
Arthritis Res Ther; 2011 Mar; 13(2):R39. PubMed ID: 21371293
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003.
Hanova P; Pavelka K; Dostal C; Holcatova I; Pikhart H
Clin Exp Rheumatol; 2006; 24(5):499-507. PubMed ID: 17181917
[TBL] [Abstract][Full Text] [Related]
15. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study.
Chuang JP; Lee JC; Leu TH; Hidajah AC; Chang YH; Li CY
BMJ Open; 2019 Oct; 9(10):e028892. PubMed ID: 31601586
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Pui K; Gow PJ; Dalbeth N
J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
[TBL] [Abstract][Full Text] [Related]
17. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM
J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929
[TBL] [Abstract][Full Text] [Related]
18. Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration.
Helget LN; England BR; Roul P; Sayles H; Petro AD; Michaud K; Mikuls TR
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1363-1371. PubMed ID: 32475070
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016.
Tsoi MF; Chung MH; Cheung BMY; Lau CS; Cheung TT
Arthritis Res Ther; 2020 Sep; 22(1):204. PubMed ID: 32887668
[TBL] [Abstract][Full Text] [Related]
20. Association of urate-lowering drugs with the risk of future urolithiasis in patients with gout: A population-based nested case-control study.
Wu SW; Liu CY; Yeh CJ; Wang YH; Cheng-Chung Wei J
Int J Clin Pract; 2021 Aug; 75(8):e14283. PubMed ID: 33914376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
